Intravascular mucinosis with mucin emboli and thrombosis accompanying adenocarcinomas

Pratt-Thomas, H.R.; Smith, Ray M.; McMaster, K.; Earlywine, G.R.

doi:10.1016/s0344-0338(80)80038-0

Cited by 10 publications

(2 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Finally, while our convenient patient sample population suggests that fibrinogen is likely the contributory cause of hypercoagulability in patients with adenocarcinoma of the pancreas, ongoing investigation is needed to validate this finding. Alternative explanations for hypercoagulability and pancreatic cancer have been from tumor derived microparticles driving thrombotic complications(36), while older data suggest that mucin from tumors is an etiology of thrombosis(37). However, neither of these hypotheses would explain why angle is increased in patient with advanced pancreatic cancer.…”

Section: Discussionmentioning

confidence: 99%

Utility of Viscoelastic Assays Beyond Coagulation: Can Preoperative Thrombelastography Indices Predict Tumor Histology, Nodal Disease, and Resectability in Patients Undergoing Pancreatectomy?

Moore¹,

Paniccia²,

Lawson³

et al. 2018

Journal of the American College of Surgeons

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Utility of Viscoelastic Assays Beyond Coagulation: Can Preoperative Thrombelastography Indices Predict Tumor Histology, Nodal Disease, and Resectability in Patients Undergoing Pancreatectomy?

Moore¹,

Paniccia²,

Lawson³

et al. 2018

Journal of the American College of Surgeons

View full text Add to dashboard Cite

show abstract

“…Patients with colloid carcinoma can develop migratory thromboembolism (ie, Trousseau syndrome) after incisional biopsy of the tumor, with a fatal outcome, as shown in one case report (6). Previous studies described the capacity of mucin to activate the coagulation cascade; during surgical intervention, release of mucin from this mucin-rich tumor into the circulation may cause thromboembolism (41). Despite this phenomenon, long-term survival after surgical resection is significantly better for patients with colloid carcinoma than for those with PDAC: the 2-year and 5-year survival rates are 70% and 28% and 57% and 12%, respectively (P = .001) (6).…”

Section: Clinical Featuresmentioning

confidence: 99%

Pancreatic Ductal Adenocarcinoma and Its Variants: Pearls and Perils

Schawkat¹,

Manning²,

Glickman³

et al. 2020

RadioGraphics

View full text Add to dashboard Cite

Pancreatic ductal adenocarcinoma (PDAC), an epithelial neoplasm derived from the pancreatic ductal tree, is the most common histologic type of pancreatic cancer and accounts for 85%-95% of all solid pancreatic tumors. As a highly lethal malignancy, it is the seventh leading cause of cancer death worldwide and is responsible for more than 300 000 deaths per year. PDAC is highly resistant to current therapies, affording patients a 5-year overall survival rate of only 7.2%. It is characterized histologically by its highly desmoplastic stroma embedding tubular and ductlike structures. On images, it typically manifests as a poorly defined hypoenhancing mass, causing ductal obstruction and vascular involvement. Little is known about the other histologic subtypes of PDAC, mainly because of their rarity and lack of specific patterns of disease manifestation. According to the World Health Organization, these variants include adenosquamous carcinoma, colloid carcinoma, hepatoid carcinoma, medullary carcinoma, signet ring cell carcinoma, undifferentiated carcinoma with osteoclast-like giant cells, and undifferentiated carcinoma. Depending on the subtype, they can confer a better or even worse prognosis than that of conventional PDAC. Thus, awareness of the existence and differentiation of these variants on the basis of imaging and histopathologic characteristics is crucial to guide clinical decision making for optimal treatment and patient management.

show abstract